Back to News
Market Impact: 0.15
CytoDyn Appoints Robert E. Hoffman As CEO; Lalezari To Focus On Research
Source: Nasdaq
Management & GovernanceHealthcare & Biotech
CytoDyn appointed Robert E. Hoffman as CEO, effective October 20, 2026. The clinical-stage biotechnology company is developing leronlimab for oncology indications; the announcement provided no further details on strategy or financial implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Before Tera’s 95% Crash, Punches Were Thrown and Warnings Missed
- SpaceX and Tesla boards form special committees to review merger
- Tesla’s stock rises as Elon Musk drops new clues about a possible SpaceX merger
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- Why is Netflix stock sliding today?